Fractyl Health Inc reported a second-quarter net loss of $25.5 million, narrowing from $27.9 million in the same period of 2025, while presenting robust clinical data for its lead candidate, Revita. The earnings miss against the analyst estimate of $(0.13) per share—actual EPS was $(0.16)—was offset by positive one-year results from the REMAIN-1 Midpoint Cohort, which showed patients maintained up to 84% of prior GLP-1-induced weight loss. This development strengthens the company’s path toward a potential U.S. Food and Drug Administration (FDA) De Novo submission in late Q4 2026.

The financial results, released on August 10, 2026, reflect a disciplined approach to capital preservation amidst advanced clinical trials. Fractyl’s cash position stood at approximately $47.1 million as of June 30, 2026, providing a runway into early 2027. This liquidity extends beyond the anticipated topline data readout from the REMAIN-1 Pivotal Cohort in early Q4 2026, reducing near-term financing risks for investors monitoring the metabolic therapeutics firm.

Financial Performance and Cost Discipline

Fractyl’s improved bottom line was primarily driven by a significant reduction in research and development (R&D) expenses. R&D costs fell to $13.8 million in Q2 2026, down from $21.2 million in Q2 2025, representing a decrease of $7.3 million. This reduction was attributed to optimized spending on both the Revita and Rejuva programs. Conversely, selling, general, and administrative (SG&A) expenses rose slightly to $5.3 million from $4.9 million, driven by higher stock-based compensation.

Adjusted EBITDA, a non-GAAP measure used by management to evaluate core operating performance, improved to negative $16.3 million from negative $24.0 million year-over-year. Despite the operational improvements, the net loss per share of $(0.16) missed the consensus estimate of $(0.13) by 23.08%, largely due to non-cash losses related to changes in the fair value of warrant liabilities.

Clinical Milestones and Regulatory Pathway

The most material update for shareholders concerns the clinical validation of Revita, a procedural therapy designed for post-GLP-1 weight maintenance. In July 2026, Fractyl reported one-year randomized data from the REMAIN-1 Midpoint Cohort. In an optimized population receiving complete duodenal ablation, Revita-treated participants maintained approximately 84% of their GLP-1-induced weight loss, compared to only 46% in the sham group. No device-related serious adverse events were observed through one year.

Additionally, open-label data from the REVEAL-1 Cohort showed patients maintaining approximately 78% of their prior weight loss after a single procedure. These findings provide direct read-through to the ongoing REMAIN-1 Pivotal Cohort, which has completed randomization. Fractyl expects to release topline six-month data from this pivotal cohort in early Q4 2026, paving the way for a potential FDA De Novo marketing application submission later that quarter.

Pipeline Progress and Commercial Readiness

Beyond Revita, Fractyl is advancing its Rejuva gene therapy platform. The lead candidate, RJVA-001, received Clinical Trial Authorization in the Netherlands in April 2026 and ethics committee approval in Australia in July 2026. First-in-human dosing is expected in the second half of 2026, subject to site activation. A second candidate, RJVA-002, remains in preclinical development.

To prepare for potential commercialization, Fractyl appointed Mike Zumdahl as Senior Vice President of Market Access and Commercial Strategy in June 2026. The company plans to detail its commercial strategy further at an Investor Day in September 2026. Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer, stated that the recent data provides confidence in the design and execution of the pivotal trials, emphasizing the goal of shifting metabolic disease treatment toward prevention and reversal.

What the Numbers Show

The divergence between the narrowed net loss and the missed EPS estimate highlights the impact of non-operational factors on Fractyl’s financial reporting. While operating expenses decreased by $7.0 million, the net loss improvement was partially offset by a $5.1 million higher non-cash loss from changes in warrant liabilities. This suggests that while core operational efficiency is improving, market-driven valuation changes continue to introduce volatility into the bottom line. Investors should focus on the Adjusted EBITDA improvement and the strong clinical signals from Revita as primary indicators of fundamental progress, rather than GAAP net loss alone.

Fractyl Health, Inc. (NASDAQ: GUTS), a clinical-stage metabolic therapeutics company, announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer, will participate in three upcoming investor conferences. The events, scheduled for July and August 2026, will focus on the company's advancements in treating obesity and type 2 diabetes (T2D).

Conference Schedule

Rajagopalan will engage in one-on-one meetings and a fireside chat at the following events:

Webcast Access

A live webcast of the Canaccord Genuity conference session will be accessible in the "Events" section of Fractyl Health’s website at http://ir.fractyl.com . The webcast will be archived and available for replay for 90 days following the live event.

Company Overview

Fractyl Health is advancing two differentiated candidates targeting the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. The company is headquartered in Burlington, Massachusetts.